<DOC>
	<DOCNO>NCT01733758</DOCNO>
	<brief_summary>This study design examine efficacy safety 2 dose level weekly subcutaneously inject albiglutide compare placebo open label reference arm daily subcutaneous injection liraglutide , Japanese subject Type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Monotherapy Study Evaluate Efficacy Safety 2 Dose Levels Albiglutide Japanese Subjects With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects diagnosis Type 2 Diabetes Mellitus , treat diet exercise stable dose 1 OAD screen Body mass index ( BMI ) 17 40 kg/ m^2 inclusive Subjects OAD naïve , HbA1c 7.0 % 10.0 % Screening Visit 2 ; subject enter study 1 OAD , HbA1c 6.5 % 9.5 % Screening HbA1c 7.0 % 10.0 % Visit 2 Creatinine clearance &gt; 30 mL/min ( calculate use CockcroftGault formula ) History type 1 diabetes mellitus •Female subject pregnant , lactating , &lt; 6 week postpartum• Clinically significant cardiovascular and/or cerebrovascular disease Current ongoing symptomatic biliary disease , clinical sign symptom pancreatitis , history chronic acute pancreatitis , determine investigator Serum amylase &gt; =3 ×ULN and/or serum lipase &gt; =2 × ULN and/or subject experience symptom possibly relate pancreatitis Prior use TZD GLP1R agonist within 4 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>albiglutide</keyword>
	<keyword>Japanese</keyword>
	<keyword>GSK716155</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>glucagon-like peptide 1</keyword>
</DOC>